The mRNA vaccines： A new era for the individualized treatment of pancreatic cancer
- VernacularTitle:mRNA疫苗：胰腺癌个性化治疗新曙光
- Author:
Xinjing WANG
1
;
Wei WANG
1
;
Baiyong SHEN
1
Author Information
- Publication Type:Journal Article
- Keywords: Pancreatic Neoplasms; mRNA Vaccine; Immunotherapy， Active
- From: Journal of Clinical Hepatology 2025;41(4):619-624
- CountryChina
- Language:Chinese
- Abstract: Pancreatic cancer is currently recognized as one of the most malignant solid tumors， with a 5-year survival rate of 13% over a long period of time， and 80% of the patients have lost the opportunity for surgery at the time of confirmed diagnosis. In addition， the efficacy of conventional radiochemotherapy and targeted therapy is limited by high tumor heterogeneity and the complex immunosuppressive microenvironment. In recent years， mRNA vaccines have become a new focus of tumor immunotherapy due to their unique technical advantages. Based on non-integrating mRNA templates， mRNA vaccines enable precise encoding of tumor neoantigens， which are efficiently expressed in the host and can induce multifaceted immune responses. As for pancreatic cancer， current studies mainly focus on the development and optimization of tumor-associated antigen vaccines and tumor-specific antigen vaccines， as well as next-generation sequencing-guided neoantigen epitope optimization， innovative targeted delivery systems， and artificial intelligence-powered predictive models for immune response， thereby promoting the application of mRNA vaccines in the precise treatment of pancreatic cancer. Further studies should make breakthroughs in the targeted blockade of critical immunosuppressive molecules within the tumor microenvironment， the precise identification of tumor-specific antigenic epitopes， and the development of highly efficient vaccines， so as to bring new hopes for patients with pancreatic cancer.
